RELX reported in-line growth for the fourth quarter with better-than-expected margins, leading to a 2% rise in shares on Feb. 12. The company upgraded its 2026 guidance and increased its share buyback by 50%. Despite market concerns, RELX continues to perform well in its STM and legal businesses with no signs of weakness.

Guidance for 2026 indicates strong growth in the scientific, technical, and medical segment, with an acceleration in the legal business reaching 9% growth in 2025. Fair value estimates for RELX have been raised, and the shares are deemed undervalued. New product launches in both segments are expected to drive growth further.

RELX shares have dropped 50% from their peak in 2025 due to market turbulence, but the company’s wide moat remains strong. The upcoming 2026 guidance suggests another year of strong growth in revenue, EBIT, and EPS. Revenue and EBIT growth is expected to exceed revenue growth in risk, STM, and legal segments, with the exhibitions business showing strong revenue growth and improved EBIT margins.

Read more at Morningstar: RELX Earnings: Just Keeps Getting Better, Shares Deeply Undervalued